PRODUCT DESCRIPTION:

Abacavir Tablets, 300 MG, are a potent nucleoside reverse transcriptase inhibitor (NRTI) used in the management of HIV-1 infection.

These tablets help to suppress the viral load, improve immune function, and reduce the risk of HIV-related complications. Manufactured under stringent GMP conditions, these tablets offer consistent bioavailability and are suitable for global ART programs.

Available in both blister strips and HDPE bottles, they meet the varied requirements of public health procurement agencies, NGOs, and government tenders.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Available in Blister Pack or HDPE Bottle (As per market requirement)
• Available Strengths:
  • Abacavir Tablets: 300 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Management of HIV-1 infection in combination with other antiretroviral agents
• As part of ART (antiretroviral therapy) regimens in adults, adolescents, and children

Side Effects:

• COMMON:
  • Headache
  • Nausea
  • Diarrhea
  • Fatigue
  • Rash
• SERIOUS (RARE):
  • Hypersensitivity reaction (HLA-B*5701 gene-associated)
  • Liver toxicity
  • Lactic acidosis
  • Severe skin reactions (e.g., Stevens-Johnson Syndrome)
• PRECAUTIONS:
  • Screen for HLA-B*5701 before initiation to reduce risk of hypersensitivity.
  • Use with caution in patients with liver dysfunction.
  • Not recommended as monotherapy—should be used in combination.
  • Regular monitoring of liver enzymes and renal function is advised.